Robério Amorim de Almeida Pondé , Guilherme de Sousa Pondé Amorim
{"title":"乙型肝炎病毒表面抗原 \"a \"决定簇的交换再探。","authors":"Robério Amorim de Almeida Pondé , Guilherme de Sousa Pondé Amorim","doi":"10.1016/j.virol.2024.110184","DOIUrl":null,"url":null,"abstract":"<div><p>The hepatitis B virus surface antigen's (HBsAg) 'a' determinant comprises a sequence of amino acid residues located in the major hydrophilic region of the S protein, whose exchanges are closely associated with compromising the antigenicity and immunogenicity of that antigen.</p><p>The HBsAg is generally present in the bloodstream of individuals with acute or chronic hepatitis B virus (HBV) infection. It is classically known as the HBV infection marker, and is therefore the first marker to be investigated in the laboratory in the clinical hypothesis of infection by this agent.</p><p>One of the factors that compromises the HBsAg detection in the bloodstream by the assays adopted in serological screening in both clinical contexts is the loss of S protein antigenicity. This can occur due to mutations that emerge in the HBV genome regions that encode the S protein, especially for its immunodominant region – the ‘a’ determinant. These mutations can induce exchanges of amino acid residues in the S protein's primary structure, altering its tertiary structure and the antigenic conformation, which may not be recognized by anti-HBs antibodies, compromising the infection diagnosis. In addition, these exchanges can render ineffective the anti-HBs antibodies action acquired by vaccination, compromise the effectiveness of the chronically HBV infected patient's treatment, and also the HBsAg immunogenicity, by promoting its retention within the cell. In this review, the residues exchange that alter the S protein's structure is revisited, as well as the mechanisms that lead to the HBsAg antigenicity loss, and the clinical, laboratory and epidemiological consequences of this phenomenon.</p></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"599 ","pages":"Article 110184"},"PeriodicalIF":2.8000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exchanges in the ‘a’ determinant of the hepatitis B virus surface antigen revisited\",\"authors\":\"Robério Amorim de Almeida Pondé , Guilherme de Sousa Pondé Amorim\",\"doi\":\"10.1016/j.virol.2024.110184\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The hepatitis B virus surface antigen's (HBsAg) 'a' determinant comprises a sequence of amino acid residues located in the major hydrophilic region of the S protein, whose exchanges are closely associated with compromising the antigenicity and immunogenicity of that antigen.</p><p>The HBsAg is generally present in the bloodstream of individuals with acute or chronic hepatitis B virus (HBV) infection. It is classically known as the HBV infection marker, and is therefore the first marker to be investigated in the laboratory in the clinical hypothesis of infection by this agent.</p><p>One of the factors that compromises the HBsAg detection in the bloodstream by the assays adopted in serological screening in both clinical contexts is the loss of S protein antigenicity. This can occur due to mutations that emerge in the HBV genome regions that encode the S protein, especially for its immunodominant region – the ‘a’ determinant. These mutations can induce exchanges of amino acid residues in the S protein's primary structure, altering its tertiary structure and the antigenic conformation, which may not be recognized by anti-HBs antibodies, compromising the infection diagnosis. In addition, these exchanges can render ineffective the anti-HBs antibodies action acquired by vaccination, compromise the effectiveness of the chronically HBV infected patient's treatment, and also the HBsAg immunogenicity, by promoting its retention within the cell. In this review, the residues exchange that alter the S protein's structure is revisited, as well as the mechanisms that lead to the HBsAg antigenicity loss, and the clinical, laboratory and epidemiological consequences of this phenomenon.</p></div>\",\"PeriodicalId\":23666,\"journal\":{\"name\":\"Virology\",\"volume\":\"599 \",\"pages\":\"Article 110184\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0042682224002058\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682224002058","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
乙型肝炎病毒表面抗原(HBsAg)的 "a "决定簇由位于 S 蛋白主要亲水区的氨基酸残基序列组成,其交换与损害该抗原的抗原性和免疫原性密切相关。HBsAg 通常存在于急性或慢性乙型肝炎病毒(HBV)感染者的血液中。它通常被称为 HBV 感染标志物,因此是临床假设感染该病原体时首先要在实验室中检测的标志物。在两种临床情况下,血清学筛查所采用的检测方法都会影响血液中 HBsAg 的检测,其中一个因素就是 S 蛋白抗原性的丧失。出现这种情况的原因可能是编码 S 蛋白的 HBV 基因组区域出现了突变,尤其是其免疫优势区域--"a "决定簇。这些突变可引起 S 蛋白一级结构中氨基酸残基的交换,改变其三级结构和抗原构象,从而可能无法被抗 HBs 抗体识别,影响感染诊断。此外,这些交换还会使通过疫苗接种获得的抗 HBs 抗体失效,影响慢性 HBV 感染者的治疗效果,并通过促进 HBsAg 在细胞内的滞留而影响其免疫原性。在这篇综述中,我们将重新审视改变 S 蛋白结构的残基交换、导致 HBsAg 抗原性丧失的机制,以及这一现象在临床、实验室和流行病学方面的后果。
Exchanges in the ‘a’ determinant of the hepatitis B virus surface antigen revisited
The hepatitis B virus surface antigen's (HBsAg) 'a' determinant comprises a sequence of amino acid residues located in the major hydrophilic region of the S protein, whose exchanges are closely associated with compromising the antigenicity and immunogenicity of that antigen.
The HBsAg is generally present in the bloodstream of individuals with acute or chronic hepatitis B virus (HBV) infection. It is classically known as the HBV infection marker, and is therefore the first marker to be investigated in the laboratory in the clinical hypothesis of infection by this agent.
One of the factors that compromises the HBsAg detection in the bloodstream by the assays adopted in serological screening in both clinical contexts is the loss of S protein antigenicity. This can occur due to mutations that emerge in the HBV genome regions that encode the S protein, especially for its immunodominant region – the ‘a’ determinant. These mutations can induce exchanges of amino acid residues in the S protein's primary structure, altering its tertiary structure and the antigenic conformation, which may not be recognized by anti-HBs antibodies, compromising the infection diagnosis. In addition, these exchanges can render ineffective the anti-HBs antibodies action acquired by vaccination, compromise the effectiveness of the chronically HBV infected patient's treatment, and also the HBsAg immunogenicity, by promoting its retention within the cell. In this review, the residues exchange that alter the S protein's structure is revisited, as well as the mechanisms that lead to the HBsAg antigenicity loss, and the clinical, laboratory and epidemiological consequences of this phenomenon.
期刊介绍:
The journal features articles on virus replication, virus-host biology, viral pathogenesis, immunity to viruses, virus structure, and virus evolution and ecology. We aim to publish papers that provide advances to the understanding of virus biology.